Browsing category:

Antiviral


The current shortage of Acyclovir, CAS number 59277-98-3, is of great concern to the medical community. As a valued and integral treatment for encephalitis, the shortage of Acyclovir for compounding pharmacies has created an urgent need for both patients and practitioners. The August 27, 2013 issue of the Neurology journal cautioned healthcare professionals to be[…]

Read More

Breaking news in the pharmaceutical world made headlines on June 12, 2013, when the Centers for Disease Control and Prevention revealed a study touting the prophylactic benefit of Tenofovir. Coined pre-exposure prophylaxis or PrEP, this study advocating the use of Tenofovir as an interventional pre-treatment was published in the Lancet in mid- June of 2013.[…]

Read More

As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]

Read More

The Hepatitis C virus is daunting in nature, affecting 180 million people worldwide and a little over 4 million people in the United States. As the leading cause of chronic liver disease, which often leads to liver cancer, hepatitis C is currently difficult to treat with success. The typical treatment for patients with hepatitis C[…]

Read More

Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]

Read More

Acyclovir, known as the brand name Xerese, is an efficacious medication used to treat herpes labialis. Known commonly as cold sores or fever blisters, this form of the herpes virus is successfully treated with Acyclovir as a combination cream, alongside hydrocortisone. Marketed by Coria Laboratories, the patent for Xerese expires on January 24, 2017. The[…]

Read More

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the[…]

Read More

Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]

Read More

The CDC announced on Tuesday September 13, 2012 that the West Nile virus outbreak, which recently hit the U.S., is showing no signs of relenting, with an astounding 35% increase in cases from last week. With 2,636 cases involving people, including 118 deaths, all states except Alaska and Hawaii have reported at least one case[…]

Read More

Entecavir, CAS# 209216-23-9 may also be known by it’s brand name Baraclude. With the patent for Bristol-Myers Squibb’s Baraclude expiring on February 21, 2015, entecavir is on track to becoming a profitable generic product. Used to treat patients with chronic hepatitis B, entecavir is considered an antiviral medication. With a staggering 2 billion people around[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service